Surabhi Dangi-Garimella, PhD

Based on the results of the MINDACT trial, investigators have concluded that chemotherapy is unnecessary in women with early-stage breast cancer who have a high clinical and low genomic risk of disease recurrence.

Research at Massachusetts General Hospital has provided vital leads that can explain drug resistance observed in breast cancer.

Researchers from Italy and France have coauthored an article in the New England Journal of Medicine that blames novel diagnostic technologies, increased access to healthcare services, and increased medical surveillance for the thyroid cancer epidemic around the world

A new study by researchers at the Institute of Cancer Research has substantiated that hormone replacement using estrogen and progesterone increases the risk of breast cancer, especially with longer use.

A new report by the Harvey L. Neiman Health Policy Institute recommends a bundled payment model for breast cancer screening, with the objective of improved patient care and a more efficient use of healthcare resources.

Factors such as insurance status and being married are significant determinants of survival compared with race/ethnicity, in patients with multiple myeloma who are less than 65 years of age.

Financial burden is a potential nonclinical adverse event in cancer patients. As patients, especially those in the lower income ranges and the middle class, struggle to meet their medical bills, the likelihood of them skipping doses or doctor’s visits is quite high.

A study by researchers at the University of California, Berkeley, found that patients who have access to the prices charged by a testing laboratory, as well as reference pricing, choose lower-cost laboratories, a move that results in overall cost savings.

A collaborative pilot that involves the California Department of Public Health, St. Joseph Health in Orange County, and UCSF Benioff Children’s Hospital in Oakland is studying whether near—real-time reporting of cancer diagnoses by pathologists, using standardized electronic forms, will permit providers to make more informed and timely treatment decisions.

The monoclonal antibody daratumumab (Darzalex) has been granted Breakthrough designation, the second for this drug, for use in combination with either lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with multiple myeloma who have received at least 1 prior therapy.

Adrenal gland tumors that are defined as being nonfunctional may not really be so, and the hormones that these tumors secrete could increase an individual’s risk of cardiometabolic irregularities, according to a new study.

Results from the CheckMate 066 study found that the checkpoint inhibitor nivolumab, which has proven highly efficient in the treatment of melanoma, also performs well in improving the patient’s long-term quality of survival benefit in patients with advanced melanoma.

Loss-of-function mutations in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), deletion of the wild-type allele of JAK1 or JAK2, and truncation in the antigen-presenting protein beta-2-microglobulin (B2M) gene have been found responsible for lack of response to interferon gamma in patients with melanoma.

Maximizing the utility of technology platforms and making them meaningful to ensure quality cancer care was the underlying theme of Emerging Issues and Opportunities in Health Information Technology, a National Comprehensive Cancer Network Policy Summit, held June 27, 2016, in Washington, DC.

Gregory C. Simon, executive director, White House Cancer Task Force, spoke at the National Comprehensive Cancer Network Policy Summit in Washington, DC. “Just like the original moonshot, the Cancer Moonshot is about using technology and the resulting information,” he said.

At the Emerging Issues and Opportunities in Health Information Technology Policy Summit hosted by the National Comprehensive Cancer Network, on June 27, 2016, an afternoon panel discussed the role of technology and its importance in promoting dissemination of data.

Survival in patients with early-stage lung cancer, particularly those with adenocarcinomas, may be shortened by air pollution, according to a study published in the journal Thorax.

A new health services study in JAMA Oncology evaluated the impact of clinical evidence on routine surveillance in ovarian cancer, and found none.

Private insurance coverage and living closer to a plastic surgeon’s office encouraged women who had a mastectomy to undergo breast reconstruction, according to a recent study.

An expert panel convened by the American Society of Clinical Oncology (ASCO) has issued a new clinical practice guideline on management of chronic pain in adult cancer survivors.

Researchers at the Thomas Jefferson University have developed an online decision-support tool called the Decision Counseling Program that can help for men diagnosed with localized, low-risk prostate cancer make treatment choices.

Pharmacy benefit managers (PBMs) and large employer organizations are taking measures to save healthcare costs in 2017, and for PBMs, formulary exclusions is a fool-proof tactic.

Nivolumab failed to perform better than chemotherapy in patients with squamous as well as non-squamous non-small cell lung cancer (NSCLC).

Scientists at the Sidney Kimmel Comprehensive Cancer Center have discovered that certain genes involved in metabolic processes are upregulated in patients with renal cell carcinoma (RCC) who are resistant to nivolumab.

Outpatient service charges are estimated to cause a 29.9% spike in healthcare premiums in 2017, much higher than the 14.3% projected for medications.

Results from the CheckMate 066 study found that the checkpoint inhibitor nivolumab performs well in improving patients' long-term quality of survival benefit in patients with advanced melanoma.

World Lung Cancer Day is a grassroots effort conceived by a lung cancer survivor. Here are a few updates on ways to prevent the disease and manage treatment.

Sharing information of diagnosis and treatment decisions reassured women newly diagnosed with breast cancer of their health choices, according to a new study published in JAMA Oncology.

A list of a few recent developments in the world of health information technology (Health IT).

A new study has found that combining ipilimumab with local peripheral treatments such as radiotherapy or electrochemotherapy can significantly better survival in patients with melanoma.